Current and Future Market for Cardiovascular Drugs: Market Size, Forecasts, Competitive Landscape.LYON, France -- Allbizreport.com announces that a new market research report related to the world wide pharmaceutical market is now available to its catalogue. The Cardiovascular Market Outlook to 2011 (www.allbizreport.com/cardiovascular-market-outlook-to-2011.htm) The Cardiovascular Market Outlook to 2011 is a new report providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market. This report offers insight into R&D trends in the cardiovascular market, including the discontinuation dis·con·tin·u·a·tion n. A cessation; a discontinuance. Noun 1. discontinuation - the act of discontinuing or breaking off; an interruption (temporary or permanent) discontinuance of key pipeline drugs such as Pfizer's torcetrapib and atorvastatin atorvastatin /ator·va·stat·in/ (ah-tor?vah-stat´in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the calcium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia. , and the development of new drug classes including Novartis' Rasilez (aliskiren), anticipated to be the first to market direct renin renin /re·nin/ (re´nin) a proteolytic enzyme synthesized, stored, and secreted by the juxtaglomerular cells of the kidney; it plays a role in regulation of blood pressure by catalyzing the conversion of angiotensinogen to angiotensin I. inhibitor. Use this report to identify the leading cardiovascular companies to 2011 and discover the cardiovascular blockbusters of the future. Key findings of the report... * Anti-hypertensives have been the highest selling portion of the cardiovascular market in 2005. * Norvasc was the leading anti-hypertensive drug in 2005, with sales of $5bn, an increase of 3.9% from 2004. * In 2006 the patents protecting Zocor and Pravachol expired, which together with the anticipated patent expiry of Lipitor in 2010, will result in a flood of generic statins Statins A class of drugs commonly used to lower LDL cholesterol levels. Mentioned in: C-Reactive Protein onto the market, heavily impacting sales of branded drugs. * Two key anti-hypertensives are forecast to launch in 2007:Novartis' Rasilez (aliskiren) and Exforge (valsartan plus amlodipine).Exforge gained FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval in December 2006 and is predicted to generate high sales. * Pfizer's torcetrapib and atorvastatin was discontinued in late 2006 due to safety concerns. * The discontinuation of torcetrapib will have an impact on the other members of the CETP CETP Cholesteryl Ester Transfer Protein CETP Certified Employee Training Program CETP Common Effluent Treatment Plant CETP China Energy Technology Program CETP Centre de Recherches en Physique de l'Environment Terrestre et Planetaire (French) inhibitor pipeline drugs, in particular Roche's JTT-705. * Pfizer is the leading global cardiovascular company, with sales of nearly $20bn in 2005, representing 15.6% of the cardiovascular market. * The largest growth seen in the cardiovascular market is from Amgen at 17.4%, with sales in 2005 of $6.4bn. Key questions answered in this report * What were the key events in the global cardiovascular market in 2005-06? * What are the drivers and resistors to growth for the key players in the market? * How has the failure of key pipeline products expected to impact the global cardiovascular market? * What strategies are the leading companies implementing to maximize sales and boost market share? * When will generic competition impact the leading cardiovascular brands? * Which new product launches are forecast to gain blockbuster status? * What will the competitive landscape in hypertension, thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. , dyslipidemia and arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of look like in 2011? Top five reasons to order your copy today * Gain up-to-date competitive intelligence across the cardiovascular area and understand the major issues affecting key pharmaceutical marketers. * Understand which cardiovascular indications have the greatest potential for growth through the 6-year forecasts in anti-hypertensive, anti-dyslipidemic, anti-thrombosis and cardiac therapy drug classes. * Assess your potential competitive position to the leading cardiovascular companies, through the report's extensive pipeline insight and profiles of upcoming launches. * Examine factors impacting pipeline drugs, such as clinical trial results, discontinued products and patient potentials. * Identify the critical success factors for your company to succeed in the cardiovascular market, through examination of winning growth strategies used by the leading players. Executive Summary Patient potential Global cardiovascular market analysis Analysis of potential future cardiovascular blockbusters Leading players in the cardiovascular market CHAPTER 1 PATIENT POTENTIAL Summary Introduction Cardiovascular risk factors Hypertension Dyslipidemia Diabetes Cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease Acute thrombotic thrombotic /throm·bot·ic/ (-bot´ik) pertaining to or affected with thrombosis. throm·bot·ic adj. Relating to, caused by, or characterized by thrombosis. events Acute coronary syndromes acute coronary syndrome n. A sudden, severe coronary event that mimics a heart attack, such as unstable angina. acute coronary syndrome Venous thromboembolism thromboembolism /throm·bo·em·bo·lism/ (-em´bo-lizm) obstruction of a blood vessel with thrombotic material carried by the blood from the site of origin to plug another vessel. throm·bo·em·bo·lism n. Stroke Cardiovascular procedures Percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty n. Abbr. PTCA A procedure for enlarging a narrowed arterial lumen by peripheral introduction of a balloon-tip catheter followed by dilation of the lumen as the inflated catheter tip is Coronary artery bypass grafting coronary artery bypass graft n. Abbr. CABG A surgical procedure in which a section of vein or other conduit is grafted between the aorta and a coronary artery below the region of an obstruction in that artery. Insertion of implantable cardioverter defibrillator defibrillator, device that delivers an electrical shock to the heart in order to stop certain forms of rapid heart rhythm disturbances (arrhythmias). The shock changes a fibrillation to an organized rhythm or changes a very rapid and ineffective cardiac rhythm to a Heart transplantation Heart Transplantation Definition Heart transplantation, also called cardiac transplantation, is the replacement of a patient's diseased or injured heart with a healthy donor heart. CHAPTER 2 GLOBAL CARDIOVASCULAR MARKET ANALYSIS Summary Introduction Key events in the global cardiovascular market, 2005-6 Pfizer discontinues torcetrapib development Genomics and new therapeutic targets New therapeutic targets Use of biomarkers/pharmacogenomics Stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young Genomics Market analysis by country Market analysis by therapy area Leading brands in the global cardiovascular market Anti-hypertensives Introduction Analysis of the leading anti-hypertensives Market analysis by drug class ACE inhibitors ACE inhibitor (ā'sē'ē`, ās) or angiotensin-converting enzyme inhibitor (ăn'jēōtĕn`sĭn) Calcium channel blockers Calcium Channel Blockers Definition Calcium channel blockers are medicines that slow the movement of calcium into the cells of the heart and blood vessels. Angiotensin receptor The angiotensin receptors are a class of G protein-coupled receptors with angiotensins as ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the main effector hormone. blockers Beta blockers Beta Blockers Definition Beta blockers are medicines that affect the body's response to certain nerve impulses. This, in turn, decreases the force and rate of the heart's contractions, which lowers blood pressure and reduces the heart's demand for Diuretics Diuretics Definition Diuretics are medicines that help reduce the amount of water in the body. Purpose Diuretics are used to treat the buildup of excess fluid in the body that occurs with some medical conditions such as congestive heart Other hypertension drugs Anti-hypertensives sales forecasts Anti-dyslipidemics Introduction Analysis of the leading anti-dyslipidemics Market analysis by drug class Statins Fibrates Non-statin products Anti-dyslipidemic sales forecasts Anti-thrombotics Introduction Analysis of the leading anti-thrombotics Market analysis by drug class Anti-platelets Heparins Vitamin K vitamin K Any of several fat-soluble compounds essential for the clotting of blood. A deficiency of vitamin K in the body leads to an increase in clotting time. In 1929 a previously unrecognized fat-soluble substance present in green leafy vegetables was found to be required antagonists antagonists, n muscles that counterbalance agonists during specific movements. opioid Neurology A pain-attenuating peptide that occurs naturally in the brain, which induces analgesia by mimicking endogenous opioids at opioid Fibrinolytics Anti-thrombotics sales forecasts Cardiac therapies Introduction Analysis of the leading cardiac therapies Market analysis by drug class Other cardiac therapies Nitrites and nitrates Anti-arrhythmics Cardiac therapies sales forecast CHAPTER 3 ANALYSIS OF POTENTIAL FUTURE CARDIOVASCULAR BLOCKBUSTERS Summary Introduction Anti-hypertensives Rasilez Exforge CHF-1521 Zanipress Clevelox Cardoxal Anti-dyslipidemics KS-01-019 Synordia Anti-thrombotics BAY-597939 Rendix Idraparinux Apixaban SSR-126517 Cardiac therapies Multaq Stedicor RSD RSD Reflex sympathetic dystrophy, see there 1235 Laszarin CHAPTER 4 LEADING PLAYERS IN THE CARDIOVASCULAR MARKET Summary Introduction Global market shares Pfizer Marketed products R&D pipeline Cardiovascular portfolio sales forecasts Strategic analysis Drivers of growth Resistors of growth M&A and licensing activity Merck & Co. Marketed products R&D pipeline Cardiovascular portfolio sales forecasts Strategic analysis Drivers of growth Resistors of growth M&A and licensing activity Sanofi-Aventis Marketed products R&D pipeline Cardiovascular portfolio sales forecasts Strategic analysis Drivers of growth Resistors of growth M&A and licensing activity Novartis Marketed products R&D pipeline Cardiovascular portfolio sales forecasts Strategic analysis Drivers of growth Resistors of growth M&A and licensing activity Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Marketed products R&D pipeline Cardiovascular portfolio sales forecasts Strategic analysis Drivers of growth Resistors of growth M&A and licensing activity Chapter 5 Appendix IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. data Index List of Figures Figure 1.1: Interaction of cardiovascular risk factors Figure 2.2: Competitive dynamics of the cardiovascular market, 2004-5 Figure 2.3: Competitive dynamics of the leading anti-hypertensives, 2004-5 Figure 2.4: Competitive dynamics of the leading anti-dyslipidemics, 2004-5 Figure 2.5: Competitive dynamics of the leading anti-thrombotics, 2004-5 Figure 2.6: Competitive dynamics of the leading cardiac therapies, 2004-5 Figure 4.7: Leading players in the cardiovascular market, 2004-5 List of Tables Table 1.1: Prevalence of hypertension in the 7 major markets, 2005 Table 1.2: Forecast prevalence of hypertension in the 7 major markets, 2006-11 Table 1.3: Lipoprotein lipoprotein (lĭp'əprō`tēn), any organic compound that is composed of both protein and the various fatty substances classed as lipids, including fatty acids and steroids such as cholesterol. families Table 1.4: Prevalence of dyslipidemia in the 7 major markets, 2005 Table 1.5: Forecast prevalence of dyslipidemia in the 7 major markets, 2006-15 Table 1.6: Prevalence of diabetes in the 7 major markets, 2005 Table 1.7: Forecast prevalence of diabetes in the 7 major markets, 2006-11 Table 1.8: Prevalence of cardiovascular disease in the 7 major markets, 2005 Table 1.9: Forecast prevalence of cardiovascular disease in the 7 major markets, 2006-11 Table 1.10: Prevalence of acute coronary syndromes in the 7 major markets, 2005 Table 1.11: Estimated incidence of VTE VTE Vocational and Technical Education VTE Venous Thrombo Embolism VTE Vacuum Thermal Evaporation VTE Vientiane, Laos - Wattay (Airport Code) VTE Virtual Terminal Environment VTE Video Transfer Engine VTE Video Tape Editing in the seven major markets, 2005 Table 1.12: Forecast incidence of VTE in the 7 major markets, 2006-11 Table 1.13: Incidence of stroke in the 7 major markets, 2005 Table 1.14: Forecast incidence of stroke in the 7 major markets, 2006-2011 Table 1.15: Prevalence of heart transplants in the US, 2000-5 Table 2.16: Global cardiovascular sales, 2004-5 Table 2.17: Global sales of key cardiovascular therapy areas, 2001-2005 Table 2.18: Global top 10 selling cardiovascular products, 2005 Table 2.19: Sales of the leading anti-hypertensives, 2004-5 Table 2.20: Patent expiries for anti-hypertensive drugs, 2006 Table 2.21: Anti-hypertensive sales by drug class, 2004-5 Table 2.22: Sales of the leading ACE inhibitors, 2004-5 Table 2.23: Sales of the leading CCBs, 2004-5 Table 2.24: Sales of the leading ARBs, 2004-5 Table 2.25: Sales of the leading beta blockers, 2004-5 Table 2.26: Sales of the leading diuretics, 2004-5 Table 2.27: Anti-hypertensives sales forecast, 2004-11 Table 2.28: Sales of the leading anti-dyslipidemics, 2004-05 Table 2.29: Anti-dyslipidemic sales by drug class, 2004-5 Table 2.30: Anti-dyslipidemics sales forecast, 2004-11 Table 2.31: Sales of the leading anti-thrombotics, 2004-5 Table 2.32: Anti-thrombotic sales by drug class, 2004-5 Table 2.33: Sales of the leading anti-platelets, 2004-05 Table 2.34: Sales of the leading heparins, 2004-05 Table 2.35: Anti-thrombotics sales forecast, 2004-11 Table 2.36: Sales of the leading cardiac therapies, 2004-05 Table 2.37: Cardiac therapies sales forecast, 2004-11 Table 3.38: Anti-hypertensives key late stage pipeline, 2006 Table 3.39: Anti-dyslipidemics key late stage pipeline, 2006 Table 3.40: Anti-thrombotic key late stage pipeline, 2006 Table 3.41: Cardiac therapy key late stage pipeline, 2006 Table 4.42: Leading players in the cardiovascular market, 2004-5 Table 4.43: Pfizer's global cardiovascular portfolio, 2004-5 Table 4.44: Pfizer's cardiovascular pipeline, 2006 Table 4.45: Forecast sales for Pfizer's cardiovascular portfolio, 2004-11 Table 4.46: Merck's global cardiovascular portfolio, 2004-5 Table 4.47: Merck's cardiovascular pipeline, 2006 Table 4.48: Forecast sales for Merck's cardiovascular portfolio, 2004-11 Table 4.49: Sanofi-Aventis' marketed portfolio, 2004-5 Table 4.50: Sanofi-Aventis' cardiovascular pipeline, 2006 Table 4.51: Forecast sales for Sanofi-Aventis' cardiovascular portfolio, 2004-11 Table 4.52: Novartis' cardiovascular portfolio, 2004-5 Table 4.53: Novartis' cardiovascular pipeline, 2006 Table 4.54: Forecast sales for Novartis' cardiovascular portfolio, 2004-11 Table 4.55: Bristol-Myers Squibb's cardiovascular portfolio, 2004-5 Table 4.56: Bristol-Myers Squibb's cardiovascular pipeline, 2006 Table 4.57: Forecast sales for Bristol-Myers Squibb's cardiovascular portfolio, 2004-11 More market research reports ? Go to http://www.allbizreport.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion